84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 81

84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

Background/Significance

Vagina/sexual health issues are common but under-recognized and understudied in women with breast cancer being treated with endocrine therapy. The EQUALS (ELAINE ESR1 QUAlity of Life Survey) explored quality of life and symptoms, biomarkers, treatment adverse effects (AEs), and patient-medical team communication of women with estrogen receptor (ER)–positive/HER2-negative metastatic breast cancer. Here, the vagina/sexual health aspects from 3 EQUALS were summarized.

Materials and Methods

EQUALS 1, 2, and 3 (EQ1, EQ2, EQ3) were sent to/posted for ER–positive/HER2-negative metastatic breast cancer patients from Cure Media Group, Facebook and Twitter groups, patient advocacy groups, authors’ contacts, and breast cancer clinic patients in June 2022 (EQ1, 42 questions), March/April 2023 (EQ2; 50 questions; mostly on vulvovaginal atrophy), and June/September 2023 (EQ3, 55 questions). Survey answers were summarized descriptively. Patients received a $10 gift card at survey completion.

Results

887 patients completed 3 EQUALS. Respondents were 19 to 83 years old; and one-third to one-half were non-White in EQ1/3, and mostly White (85%) in EQ2. Half to three quarters lived in urban/suburban settings; three-quarters had higher education. Patients had 1 to 4 treatment lines for metastatic breast cancer.

Vaginal symptoms were reported by 61% of patients and associated with breast cancer treatment for a mean of 4.8 years (EQ2). The most bothersome symptoms were vaginal dryness (33%), painful intercourse (14%), and vaginal itching (10%). AEs impacting quality of life were vaginal atrophy/dryness (36% to 47%) in EQ1/3, and sexual dysfunction (45%) in EQ3.

Sexual intimacy worried 64% of patients in EQ1; vaginal/sexual AEs concerned 80% in EQ2; and sexual dysfunction concerned 27% in EQ3. More than half (60%) of patients said metastatic breast cancer or its treatment negatively impacted intimate/sexual relationships in EQ1. In EQ2, vaginal/sexual AEs negatively impacted sexual intercourse frequency (61%) and self-esteem (64%), and made 51% feel isolated. Commonly reported effects of vaginal/sexual AEs were limited enjoyment of sexual activity (39%), painful intercourse (33%), and vaginal burning/itching (32%). Half (54%) of patients never/almost never felt sexual desire/interest in the past month, especially when prior endocrine therapy negatively impacted their sexual health (61%); low sexual desire bothered 56%.

In EQ1/2, 31% to 61% of patients were uncomfortable discussing vaginal/sexual AEs with their medical team. In EQ2, approximately one-third felt poorly informed by their medical team (38%) and poorly equipped to improve these AEs (33%). More patients in EQ1/2 were comfortable discussing these AEs, and in EQ2, more felt well informed by their medical team, if their oncologist was female.

Most (93%, EQ2) were interested in an FDA-approved, well-tolerated, breast cancer treatment that improved vaginal/sexual health.

Conclusion

Women treated for ER–positive/HER2-negative metastatic breast cancer experienced and were concerned about vaginal/sexual AEs, which negatively impacted their intimate/sexual relationships. Many were uncomfortable discussing these symptoms with their medical team and felt poorly informed/equipped to manage them.

Articles in this issue

39 Development and Validation of a Questionnaire to Assess Motivation and Satisfaction in Mastectomy Patients With or Without Reconstruction
39 Development and Validation of a Questionnaire to Assess Motivation and Satisfaction in Mastectomy Patients With or Without Reconstruction
40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data
40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data
41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists
41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists
42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US
42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US
TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery
45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status
48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status
49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval
49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval
52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer
52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer
53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy
53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy
54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial
54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial
55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?
55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?
56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?
56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?
57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers
57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers
Recent Videos
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content